1. Home
  2. BLDE vs ZNTL Comparison

BLDE vs ZNTL Comparison

Compare BLDE & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLDE
  • ZNTL
  • Stock Information
  • Founded
  • BLDE 2014
  • ZNTL 2014
  • Country
  • BLDE United States
  • ZNTL United States
  • Employees
  • BLDE N/A
  • ZNTL N/A
  • Industry
  • BLDE Aerospace
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLDE Consumer Discretionary
  • ZNTL Health Care
  • Exchange
  • BLDE Nasdaq
  • ZNTL Nasdaq
  • Market Cap
  • BLDE 276.7M
  • ZNTL 273.1M
  • IPO Year
  • BLDE N/A
  • ZNTL 2020
  • Fundamental
  • Price
  • BLDE $3.16
  • ZNTL $3.47
  • Analyst Decision
  • BLDE Buy
  • ZNTL Buy
  • Analyst Count
  • BLDE 1
  • ZNTL 8
  • Target Price
  • BLDE $6.00
  • ZNTL $10.50
  • AVG Volume (30 Days)
  • BLDE 626.1K
  • ZNTL 1.6M
  • Earning Date
  • BLDE 11-12-2024
  • ZNTL 11-12-2024
  • Dividend Yield
  • BLDE N/A
  • ZNTL N/A
  • EPS Growth
  • BLDE N/A
  • ZNTL N/A
  • EPS
  • BLDE N/A
  • ZNTL N/A
  • Revenue
  • BLDE $241,814,000.00
  • ZNTL $40,560,000.00
  • Revenue This Year
  • BLDE $12.14
  • ZNTL N/A
  • Revenue Next Year
  • BLDE $11.35
  • ZNTL N/A
  • P/E Ratio
  • BLDE N/A
  • ZNTL N/A
  • Revenue Growth
  • BLDE 12.04
  • ZNTL N/A
  • 52 Week Low
  • BLDE $2.45
  • ZNTL $2.66
  • 52 Week High
  • BLDE $4.25
  • ZNTL $18.07
  • Technical
  • Relative Strength Index (RSI)
  • BLDE 37.44
  • ZNTL 49.60
  • Support Level
  • BLDE $3.18
  • ZNTL $3.65
  • Resistance Level
  • BLDE $3.76
  • ZNTL $4.44
  • Average True Range (ATR)
  • BLDE 0.24
  • ZNTL 0.42
  • MACD
  • BLDE -0.06
  • ZNTL 0.04
  • Stochastic Oscillator
  • BLDE 5.75
  • ZNTL 45.51

About BLDE Blade Air Mobility Inc.

Blade Air Mobility Inc is a technology-powered air mobility platform that provides air transportation and logistics for hospitals and is a transporter of human organs for transplant, and for passengers, with helicopter and fixed-wing services predominantly in the Northeast United States, Southern Europe and Western Canada. The company's operating segments are; Passenger, and Medical. Majority of the revenue for the company is generated from its Medical segment which predominantly consists of transportation of human organs for transplant and the medical teams supporting these services. It also offers additional services including donor logistics coordination and support in evaluating potential donor organs. A substantial portion of the company's revenue is generated from the United States.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Share on Social Networks: